|
249
|
945
|
4anuA |
Complexes of pi3kgamma with isoform selective inhibitors. |
|
212
|
916
|
4ajwA |
Discovery and optimization of new benzimidazole- and benzoxazole-pyrimidone selective pi3kbeta inhibitors for the treatment of phosphatase and tensin homologue (pten)-deficient cancers |
|
206
|
952
|
4aofA |
Selective small molecule inhibitor discovered by chemoproteomic assay platform reveals regulation of th17 cell differentiation by pi3kgamma |
|
256
|
945
|
4anwA |
Complexes of pi3kgamma with isoform selective inhibitors. |
|
280
|
940
|
3zimA |
Discovery of a potent and isoform-selective targeted covalent inhibitor of the lipid kinase pi3kalpha |
|
274
|
949
|
3zvvA |
Fragment bound to pi3kinase gamma |
|
249
|
946
|
4anvA |
Complexes of pi3kgamma with isoform selective inhibitors. |
|
282
|
947
|
3zw3A |
Fragment based discovery of a novel and selective pi3 kinase inhibitor |
|
250
|
950
|
3tjpA |
Crystal structure of pi3k gamma with n6-(3,4-dimethoxyphenyl)-2-morpholino-[4,5'-bipyrimidine]-2',6-diamine |
|
258
|
949
|
3tl5A |
Discovery of gdc-0980: a potent, selective, and orally available class i phosphatidylinositol 3-kinase (pi3k)/mammalian target of rapamycin (mtor) kinase inhibitor for the treatment of cancer |
|
270
|
949
|
3t8mA |
Rational design of pi3k-alpha inhibitors that exhibit selectivity over the pi3k-beta isoform |
|
251
|
949
|
3sd5A |
Crystal structure of pi3k gamma with 5-(2,4-dimorpholinopyrimidin-6-yl)-4-(trifluoromethyl)pyridin-2-amine |
|
261
|
945
|
3s2aA |
Crystal structure of pi3k-gamma in complex with a quinoline inhibitor |
|
284
|
924
|
6q74A |
Pi3k delta in complex with 1benzyln[5(3,6dihydro2hpyran4yl)2methoxypyridin3yl]2methyl1himidazole4sulfonamide |
|
269
|
949
|
3r7qA |
Structure-based design of thienobenzoxepin inhibitors of pi3- kinase |
|
268
|
949
|
3r7rA |
Structure-based design of thienobenzoxepin inhibitors of pi3-kinase |
|
332
|
1052
|
5ukjA |
The co-structure of n,n-dimethyl-4-[(6r)-6-methyl-5-(1h-pyrrolo[2,3- b]pyridin-4-yl)-4,5,6,7-tetrahydropyrazolo[1,5- a]pyrazin-3-yl]benzenesulfonamide and a rationally designed pi3k-alpha mutant that mimics atr |
|
327
|
1052
|
5ul1A |
The co-structure of 3-amino-6-(4-((1-(dimethylamino)propan-2-yl)sulfonyl)phenyl)-n-phenylpyrazine-2-carboxamide and a rationally designed pi3k-alpha mutant that mimics atr |
|
334
|
1056
|
5uk8A |
The co-structure of (r)-4-(6-(1-(cyclopropylsulfonyl)cyclopropyl)-2-(1h-indol-4-yl)pyrimidin-4-yl)-3-methylmorpholine and a rationally designed pi3k-alpha mutant that mimics atr |
|
303
|
944
|
5ubrA |
Crystal structure of pi3k alpha in complex with a 7-(3-(piperazin-1-yl)phenyl)pyrrolo[2,1-f][1,2,4] triazin-4-amine deriviatine |
|
273
|
1013
|
5ubtA |
Crystal structure of pi3k delta in complex with a 7-(3-(piperazin-1-yl)phenyl)pyrrolo[2,1-f][1,2,4] triazin-4-amine deriviatine |
|
274
|
1015
|
5t8fA |
P110delta/p85alpha with taselisib (gdc-0032) |
|
293
|
1083
|
5sxbA |
Crystal structure of pi3kalpha in complex with fragment 23 |
|
284
|
1078
|
5sxjA |
Crystal structure of pi3kalpha in complex with fragment 29 |
|
309
|
1081
|
5sxdA |
Crystal structure of pi3kalpha in complex with fragment 22 |
|
303
|
1080
|
5sx9A |
Crystal structure of pi3kalpha in complex with fragment 14 |
|
286
|
1085
|
5sxaA |
Crystal structure of pi3kalpha in complex with fragment 10 |
|
251
|
919
|
5t2gA |
Mpi3kd in complex with 7i |
|
240
|
916
|
5t8iA |
Pi3kdelta in complex with the inhibitor gs-9901 |
|
309
|
1079
|
5swgA |
Crystal structure of pi3kalpha in complex with fragments 5 and 21 |
|
261
|
919
|
5t2iA |
Mpi3kd in complex with 7k |
|
301
|
1079
|
5sxkA |
Crystal structure of pi3kalpha in complex with fragment 18 |
|
302
|
1083
|
5sxiA |
Crystal structure of pi3kalpha in complex with fragment 13 |
|
291
|
1081
|
5sxeA |
Crystal structure of pi3kalpha in complex with fragments 19 and 28 |
|
286
|
1081
|
5swpA |
Crystal structure of pi3kalpha in complex with fragments 6 and 24 |
|
260
|
919
|
5t27A |
Mpi3kd in complex with 5d |
|
262
|
918
|
5t7fA |
Pi3kdelta in complex with the inhibitor gs-643624 |
|
304
|
1082
|
5swtA |
Crystal structure of pi3kalpha in complex with fragments 17 and 27 |
|
257
|
919
|
5t28A |
Mpi3kd in complex with 5k |
|
291
|
1081
|
5sx8A |
Crystal structure of pi3kalpha in complex with fragments 12 and 15 |
|
305
|
1079
|
5swrA |
Crystal structure of pi3kalpha in complex with fragments 20 and 26 |
|
299
|
1078
|
5sxfA |
Crystal structure of pi3kalpha in complex with fragment 9 |
|
282
|
1079
|
5sxcA |
Crystal structure of pi3kalpha in complex with fragment 8 |
|
259
|
919
|
5t2bA |
Mpi3kd in complex with 5e |
|
254
|
919
|
5t2dA |
Mpi3kd in complex with 7j |
|
253
|
942
|
5t23A |
Pi3kg in complex with 5d |
|
278
|
1080
|
5sw8A |
Crystal structure of pi3kalpha in complex with fragments 7 and 11 |
|
240
|
919
|
5t2mA |
Mpi3kd in complex with 7m |
|
264
|
947
|
5oq4A |
Pqr309 - a potent, brain-penetrant, orally bioavailable, pan-class i pi3k/mtor inhibitor as clinical candidate in oncology |
|
240
|
919
|
5o83A |
Discovery of cdz173 (leniolisib), representing a structurally novel class of pi3k delta-selective inhibitors |
